Several exciting enhancements were made to the Citeline map visualizations to increase their overall value and usability.  The enhancements are summarized below:

1. Distribution of heatmap data is clearer with more differentiated colors:

2. Ability to export the map visuals to JPEG or PNG for use in proposals, presentations, and reports to support decision making:

3. Addition of new datapoints and charts to the Sitetrove map to enable new popular use cases:

• Analyze multiple data points about investigators and organizations in one dynamic, interactive visual
• Evaluate locations and workload for a subset of investigators based on associated trial statuses – quickly
• Visualize the competitive landscape based on drug attributes, such as therapeutic class or mechanism of action

Now that we are approximately mid-way through 2020, the Pharmaprojects team added the 2020 data point to the Trends dashboard:

Use this dashboard to quickly and easily analyze trends over time for your specific search – whether based on a company, therapeutic area/disease, mechanism of action, and more.

The Trends view presents a separate set of data within Pharmaprojects that contains a series of snapshots of Pharmaprojects’ data, taken each year in May from 1995 to date. It can be used to easily analyze how the R&D pipeline has changed over the past couple of decades.

COVID-19 trials segmented by severity

Five additional patient segments have been applied across our COVID-19 coverage, enabling you to find trials enrolling patients with different levels of symptom severity. The segments and their corresponding definitions are:

• Asymptomatic COVID-19: Trials enrolling subjects with confirmed COVID-19 that are asymptomatic at screening.
• Mild COVID-19: Trials enrolling subjects with confirmed COVID-19 that have mild upper respiratory symptoms at trial screening.
• Moderate COVID-19: Trials enrolling subjects with confirmed COVID-19 that have moderate symptoms (respiratory symptoms but supplemental oxygen not needed) at screening.
• Severe COVID-19: Trials enrolling subjects with confirmed COVID-19 that have severe symptoms (requiring supplemental oxygen) at screening.
• Critical COVID-19: Trials enrolling subjects with confirmed COVID-19 that have severe symptoms at screening and are in the ICU for critical support. These subjects are likely already on ventilatory support.

Hand eczema patient segment added in atopic dermatitis

An additional patient segment has been added to our atopic dermatitis disease trials, increasing granularity and allowing you to drill down specifically to trials where patients have hand eczema/dermatitis.

Existing molecular subtype patient segments in oncology expanded to all tumor types

Molecular subtype patient segments which were previously only associated with the diseases where most of the targeted drug development against those specific mutations has been focused (for example, breast and gastric cancer for HER2), have now been extended across all relevant trials, irrespective of tumor type. Searching for all patient segments which contain HER2 positive, HER2 negative, ALK, EGFR and BRAF will now return all of these trials together, or you can search within any of these disease-specific patient segments to return those specific trials of interest.

Additional psoriasis patient segments available

You can now search using five additional patient segments within our psoriasis disease. These new segments allow you to find trials enrolling patients with specific types of psoriasis which were previously indexed in the Other Psoriasis segment, allowing much greater specificity in your search.

The new segments are:

• Nail psoriasis: Trials specifying the inclusion/enrollment of patients with psoriasis affecting the finger/toenails and/or trials evaluating nail psoriasis endpoints.
• Palmoplantar (non-pustular): Trials specifying the inclusion/enrollment of patients with non-pustular psoriasis affecting the palms of the hands/soles of the feet and/or trials evaluating non-pustular palmoplantar psoriasis endpoints.
• Palmoplantar pustulosis: Trials specifying the inclusion/enrollment of patients with palmoplantar pustulosis or localized pustular psoriasis affecting the palms of the hands/soles of the feet and/or trials evaluating palmoplantar pustulosis endpoints. Signs and symptoms include blisters and fluid-filled bumps known as pustules on one or both hands and/or feet.
• Generalized pustular: Trials specifying the inclusion/enrollment of patients with generalized pustular psoriasis and/or trials evaluating pustular psoriasis endpoints. This is a rare form of psoriasis characterized by sterile, pus-filled blisters (not patches or plaques) covering most of the body. Acute generalized pustular psoriasis is also known as von Zumbusch psoriasis.
• Erythrodermic: Trials specifying the inclusion/enrollment of patients with erythrodermic psoriasis (psoriatic erythroderma) and/or trials evaluating erythrodermic psoriasis endpoints. This is a rare and particularly inflammatory form of psoriasis that often affects most of the body surface. It may occur in association with von Zumbusch pustular psoriasis.